Sangamo Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 8.42 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $744.90K. The average tenure of the management team and the board of directors is 2.4 years and 5 years respectively.
Anahtar bilgiler
Sandy Macrae
İcra Kurulu Başkanı
US$2.4m
Toplam tazminat
| CEO maaş yüzdesi | 29.9% |
| CEO görev süresi | 8.4yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 2.4yrs |
| Yönetim Kurulu ortalama görev süresi | 5yrs |
Son yönetim güncellemeleri
Recent updates
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Oct 23
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Oct 21There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$250m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
Tazminat ve Piyasa: Sandy's total compensation ($USD2.39M) is about average for companies of similar size in the US market ($USD2.41M).
Tazminat ve Kazançlar: Sandy's compensation has been consistent with company performance over the past year.
CEO
Sandy Macrae (61 yo)
8.4yrs
Görev süresi
US$2,392,272
Tazminat
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 8.4yrs | US$2.39m | 0.19% $ 744.9k | |
| Senior VP | 5.4yrs | US$1.06m | 0.036% $ 140.3k | |
| Senior VP & Chief Development Officer | 5.8yrs | US$1.03m | 0.044% $ 170.8k | |
| Head of Research | less than a year | Veri yok | 0.014% $ 54.5k | |
| Head of Technology | less than a year | Veri yok | 0.018% $ 71.7k | |
| Head of Corporate Communications & Investor Relations Officer | no data | Veri yok | Veri yok | |
| Senior VP | 3.3yrs | Veri yok | 0.041% $ 161.2k | |
| Head of Technical Operations | 1.5yrs | Veri yok | Veri yok | |
| Head of Business Development & Alliance Management | less than a year | Veri yok | Veri yok | |
| Scientist II - Discovery & Translational Research | no data | Veri yok | Veri yok | |
| Vice President of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok |
2.4yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: SGMO's management team is considered experienced (2.4 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 8.4yrs | US$2.39m | 0.19% $ 744.9k | |
| Independent Chairwoman of the Board | 10.4yrs | US$99.28k | 0.030% $ 117.7k | |
| Independent Director | 8.4yrs | US$80.53k | 0.024% $ 93.2k | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Independent Director | 6.4yrs | US$76.78k | 0.025% $ 97.9k | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5yrs | Veri yok | Veri yok |
5.0yrs
Ortalama Görev Süresi
66.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SGMO's board of directors are considered experienced (5 years average tenure).